Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $7.00 Consensus Target Price from Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has been given a consensus recommendation of "Hold" by the six analysts that are covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $7.00.

A number of analysts recently issued reports on the stock. Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price objective for the company. Needham & Company LLC restated a "buy" rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th.

Recursion Pharmaceuticals Trading Up 2.2%

RXRX stock traded up $0.14 during midday trading on Friday, hitting $6.54. The company's stock had a trading volume of 37,133,411 shares, compared to its average volume of 17,509,706. The company's fifty day moving average price is $4.92 and its 200 day moving average price is $6.00. Recursion Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a quick ratio of 4.11, a current ratio of 4.11 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business's revenue was up 7.2% on a year-over-year basis. During the same period last year, the company posted ($0.39) EPS. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Brighton Jones LLC lifted its position in shares of Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after buying an additional 6,699 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Recursion Pharmaceuticals by 17.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company's stock valued at $15,372,000 after purchasing an additional 333,323 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Recursion Pharmaceuticals by 45.7% during the 4th quarter. Victory Capital Management Inc. now owns 39,913 shares of the company's stock worth $270,000 after purchasing an additional 12,519 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $163,000. Finally, Raymond James Financial Inc. purchased a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $609,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.